Findings

What do systematic reviews say?

2,209 questions · 2,322 findings · 227 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 644 · 27.7%GRADE not reported 135 · 5.8%Very low 591 · 25.5%Low 582 · 25.1%Moderate 309 · 13.3%High 61 · 2.6%

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (dichotomous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Corticosteroids vs placebo

Clinical improvement (continuous) · inactive EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 269 participants
Very low

Nebulized budesonide vs viscous budesonide

Endoscopic improvement (continuous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulized budesonide vs viscous budesonide

Withdrawals due to adverse events · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Viaskin milk patch vs placebo

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Clinical improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Histological improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Motivational interviewing vs other active intervention

Extent of substance use at short‐term · people with substance use (adults, young adults, adolescents)

2 findings from 1 review

Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 338 participants
Low
Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 2795 participants
Low

Motivational interviewing vs other active intervention

Extent of substance use at medium‐term · people with substance use (adults, young adults, adolescents)

1 finding from 1 review

Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 2352 participants
Low

Motivational interviewing vs other active intervention

Extent of substance use at long‐term · people with substance use (adults, young adults, adolescents)

1 finding from 1 review

Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1908 participants
Low

Motivational interviewing vs other active intervention

Readiness to change (0‐ to 3‐month · people with substance use (adults, young adults, adolescents)

1 finding from 1 review

Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 988 participants
Low

Motivational interviewing vs other active intervention

Retention in treatment · people with substance use (adults, young adults, adolescents)

1 finding from 1 review

Motivational interviewing for substance use reduction 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 1945 participants
Moderate

SPLINT vs No active treatment (control)

CTS symptoms (Boston CTS questionnaire) ‐ short‐term improvement: < 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

1 finding from 1 review

Splinting for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 306 participants
Low

SPLINT vs No active treatment (control)

CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

1 finding from 1 review

Splinting for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 144 participants
Very low

SPLINT vs No active treatment (control)

Function (Boston CTS questionnaire) ‐ Long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · carpal tunnel syndrome

1 finding from 1 review

Splinting for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low